Aliskiren binds to renin and prorenin bound to (pro)renin receptor in vitro

Hypertension Research

Volumn 33, Issue 10, 2010, Pages 1053-1059

  Biswas, Kazal Boron ^a   Nabi, Ahm Nurun ^a   Arai, Yoshie ^a   Nakagawa, Tsutomu ^a   Ebihara, Akio ^a   Ichihara, Atsuhiro ^b   Watanabe, Toshifumi ^c   Inagami, Tadashi ^d   Suzuki, Fumiaki ^a  

^a GIFU UNIVERSITY   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NOVARTIS PHARMA K K   (Japan)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

(pro)renin receptor; aliskiren; direct renin inhibitor

Indexed keywords

ALISKIREN; PRORENIN; PRORENIN RECEPTOR; RENIN; RENIN INHIBITOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG RECEPTOR BINDING; IC 50; IN VITRO STUDY; LIGAND BINDING; NONHUMAN; SURFACE PLASMON RESONANCE;

AMIDES; FUMARATES; HUMANS; LIGANDS; PROTEIN BINDING; RECEPTORS, CELL SURFACE; RENIN; TIME FACTORS; VACUOLAR PROTON-TRANSLOCATING ATPASES;

EID: 77957695178     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2010.136     Document Type: Article

References (41)

1. Re RN. Cellular biology of the renin-angiotensin systems. Arch Intern Med 1984; 144: 2037-2041.
2. Lever AF. Renin: endocrine, paracrine, or part-paracrine control of blood pressure? Am J Hypertens 1989; 2: 276-285.
3. Campbell DJ. Extrarenal renin and blood pressure regulation: an alternative viewpoint. Am J Hypertens 1989; 2: 266-275.
4. Baxter JD, Perloff D, Hsueh W, Biglieri EG. The endocrinology of hypertension. In: Felig P, Baxter JD and Frohman LA (eds). Endocrinology and Metabolism. 3rd edn. McGraw-Hill: New York, 1995, pp 749-853.
5. Lutterotti NV, Catanzaro DF, Sealey JE, Laragh JH. Renin is not synthesized by cardiac and extrarenal vascular tissues: a review of experimental evidence. Circulation 1994; 89: 458-470.
6. Prieto-Carrasquero MC, Harrison-Bernard LM, Kobori H, Ozawa Y, Hering-Smith KS, Hamm LL, Navar LG. Enhancement of collecting duct renin in angiotensin II-dependent hypertensive rats. Hypertension 2004; 44: 223-229.
7. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002; 109: 1417-1427.
8. van Kesteren CAM, Danser AHJ, Derkx FHM, Dekkers DHW, Lamers JMJ, Saxena PR, Schalekamp MADH. Mannose 6-phosphate receptor-mediated internalization and activation of prorenin by cardiac cells. Hypertension 1997; 30: 1389-1396.
9. Nurun NA, Uddin MN, Nakagawa T, Iwata H, Ichihara A, Inagami T, Suzuki F. Role of 'handle' region of prorenin prosegment in the non-proteolytic activation of prorenin by binding to membrane anchored (pro)renin receptor. Front Biosci 2007; 12: 4810-4817.
10. Batenburg WW, Krop M, Garrelds IM, de Vries R, de Bruin RJ, Burckl CA, Müller DN, Bader M, Nguyen G, Danser AH. Prorenin is the endogenous agonist of the (pro)renin receptor. Binding kinetics of renin and prorenin in rat vascular smooth muscle cells overexpressing the human (pro)renin receptor. J Hypertens 2007; 25: 2441-2453.
11. Nabi AHMN, Kageshima A, Uddin MN, Nakagawa T, Park EY, Suzuki F. Binding properties of rat prorenin and renin to the recombinant rat renin/prorenin receptor prepared by a baculovirus expression system. Int J Mol Med 2006; 8: 483-488.
12. Ichihara A, Sakoda M, Mito-Karauchi A, Itoh H. Activated prorenin as therapeutic target for diabetic nephropathy. Diab Res Clin Prac 2008; 825: S63-S66.
13. Ichihara A, Hayashi M, Kaneshiro Y, Suzuki F, Nakagawa T, Tada Y, Koura Y, Nishiyama A, Okada H, Uddin MN, Nabi AHMN, Ishida Y, Inagami T, Saruta T. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the 'handle' region for non-proteolytic activation of prorenin. J Clin Invest 2004; 114: 1128-1135.
14. Satofuka S, Ichihara A, Nagai N, Koto T, Shinoda H, Noda K, Ozawa Y, Inoue M, Tsubota K, Itoh H, Oike Y, Ishida S. Role of nonproteolytically activated prorenin in pathologic, but not physiologic, retinal neovascularization. Invest Ophthalmol Vis Sci 2007; 48: 422-429.
15. Azizi M, Menard J. Combined blockade of the renin-angiotensin system with angio-tensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation 2004; 109: 2492-2499.
16. Mooser V, Nussberger J, Jullierat L. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol 1990; 15: 276-282.
17. Gradman A, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005; 111: 1012-1018.
18. Stanton A, Jensen C, Nussberger J, O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003; 42: 1137-1143.
19. Pilz B, Shagdarsuren E, Wellner M, Fiebeler A, Dechend R, Gratze P, Meiners S, Feldman DL, Webb RL, Garrelds IM, Danser AHJ, Luft F, Müller DN. Aliskiren a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005; 46: 569-576.
20. Wood JM, Maibaum J, Rahuel J, Grütter MG, Cohen NC, Rasetti V, Rüger H, Göschke R, Stutz S, Fuhrer W, Schilling W, Rigollier P, Yamaguchi Y, Cumin F, Baum HP, Schnell CR, Herold P, Mah R, Jensen C, O'Brien E, Stanton A, Bedigian MP. Structure-based design of aliskiren a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003; 308: 698-705.
21. Rahuel J, Rasetti V, Maibaum J, Rüeger H, Göschke R, Cohen NC, Stutz S, Cumin F, Fuhrer W, Wood JM, Grütter MG. Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chem Biol 2000; 7: 493-504.
22. Jeunemaitre X, Menard J, Nussberger J, Guyene TT, Brunner HR, Corvol P. Plasma angiotensins, renin, and blood pressure during acute renin inhibition by CGP 38 560A in hypertensive patients. Am J Hypertens 1989; 2: 819-827.
23. Nabi AHMN, Biswas KB, Nakagawa T, Ichihara A, Inagami T, Suzuki F. Prorenin has high affinity multiple binding sites for (pro)renin receptor. Biochim Biophys Acta 2009; 1794: 1838-1847.
24. Nakagawa T, Nishiuchi K, Akaki J, Iwata H, Satou R, Suzuki F, Nakamura Y. Efficient production of recombinant human (pro)renin utilizing a decahistidine tag attached at the C-terminus. Biosci Biotechnol Biochem 2007; 71: 256-260.
25. Biswas KB, Nabi AHMN, Arai Y, Nakagawa T, Ebihara A, Suzuki F. Species specificity of prorenin binding to the (pro)renin receptor in vitro. Front Biosci 2010; E2: 1234-1240.
26. Nagase M, Suzuki F, Sawai Y, Orihashi T, Inui Y, Nakagawa T, Nakamura Y. Purification and some properties of recombinant sheep angiotensinogen expressed in Chinese hamster ovary cells. Biomed Res 1997; 18: 439-443.
27. Suzuki F, Yamashita S, Takahashi A, Ito M, Miyazaki S, Nagata Y, Nakamura Y. Highly sensitive microplate-ELISA for angiotensin I using 3,3¢,5,5¢-tetramethylbenzidine. Clin Exp Hypertens A 1990; 12: 83-95.
28. Hummerich W, Krause DK. Improvement of renin determination in human plasma using a commonly available renin standard a radioimmunological method. Klin Wochenschr 1975; 53: 559-569.
29. Sealey JE, Laragh JH. Searching out low renin patients: limitations of some commonly used methods. Am J Med 1973; 55: 303-314.
30. Skinner SL. Improved assay methods for renin 'concentration' and 'activity' in human plasma. Methods using selective denaturation of renin substrate. Circ Res 1967; 20: 391-402.
31. Nabi AHMN, Biswas KB, Nakagawa T, Ichihara A, Ianagami T, Suzuki F. 'Decoy peptide' region (RIFLKRMPSI) of prorenin prosegment plays a crucial role in prorenin binding to the (pro)renin receptor. Int J Mol Med 2009; 24: 83-89.
32. Suzuki F, Hayakawa M, Nakagawa T, Nasir UM, Ebihara A, Iwasawa A, Ishida Y, Nakamura Y, Murakami K. Human prorenin has 'gate and handle' regions for its non-proteolytic activation. J Biol Chem 2003; 278: 22217-22222.
33. Danser AHJ, Batenburg WW, van Esch JHM, Krop M. Prorenin anno 2008. J Mol Med 2008; 86: 655-658.
34. Nabi AHMN, Suzuki F. Biochemical properties of renin and prorenin binding to the (pro)renin receptor. Hypertens Res 2010; 33: 91-97.
35. Feldt S, Batenburg WW, Mazak I, Maschke U, Wellner M, Kvakan H, Dechend R, Fiebeler A, Burckle C, Contrepas A, Danser AHJ, Bader M, Nguyen G, Luft FC, Muller DN. Prorenin and renin-induced ERK 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension 2008; 51: 682-688.
36. Krop M, Garrelds IM, de Bruin RJA, van Gool JMG, Fisher NDL, Hollenberg NK, Danser AHJ. Aliskiren accumulates in renin secretory granules and binds plasma prorenin. Hypertension 2008; 52: 1076-1083.
37. Franken AAM, Derkx FHM, Man in't veld AJ, Hop WCJ, van Rens GH, Peperkamp E, de Jong PTVM, Schalekamp MADH. High plasma prorenin in diabetes mellitus and its correlation with some complications. J Clin Endocrinol Metab 1990; 71: 1008-1015.
38. Makimattila S, Summanen P, Matinlauri I, Mantysaari M, Schlenzka A, Aalto M, Irjala K, Yki-Jarvinen H. Serum total renin, an independent marker of the activity and severity of retinopathy in patients with IDDM. Br J Ophthalmol 1998; 82: 939-944.
39. Ichihara A, Kaneshiro Y, Takemitsu T, Sakoda M, Nakagawa T, Nishiyama A, Kawachi H, Shimizu F, Inagami T. Contribution of non-proteolytically activated prorenin in glomeruli to hypertensive renal damage. J Am Soc Nephrol 2006; 17: 2495-2503.
40. Nakamura N, Satomura S, Matsuura S, Murakami K. Identification of the active site of human renin with use of new fluorogenic peptides. J Biochem 1991; 109: 741-745.
41. Nabi AH, Uddin MN, Nakagawa T, Orihashi T, Ebihara A, Iwasawa A, Nakamura Y, Suzuki F. Roles of His9 (P2 subsite) and His13 (P3¢ subsite) in angiotensinogen for catalytic reaction of renin. Int J Mol Med 2005; 16: 103-107.